The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases.
Open accessAbstract
The success of solid tumor growth and metastasis is dependent upon angiogenesis. Neovascularization within the tumor is regulated, in part, by a dual and opposing system of angiogenic and angiostatic factors. We now report that IP-10, a recently described angiostatic factor, as a potent angiostatic factor that regulates non-small cell lung cancer (NSCLC)-derived angiogenesis, tumor growth, and spontaneous metastasis. We initially found significantly elevated levels of IP-10 in freshly isolated human NSCLC samples of squamous cell carcinoma (SCCA). In contrast, levels of IP-10 were equivalent in either normal lung tissue or adenocarcinoma specimens. The neoplastic cells in specimens of SCCA were the predominant cells that appeared to express IP-10 by immunolocalization. Neutralization of IP-10 in SCCA tumor specimens resulted in enhanced tumor-derived angiogenic activity. Using a model of human NSCLC tumorigenesis in SCID mice, we found that NSCLC tumor growth was inversely correlated with levels of plasma or tumor-associated IP-10. IP-10 in vitro functioned as neither an autocrine growth factor nor as an inhibitor of proliferation of the NSCLC cell lines. Reconstitution of intratumor IP-10 for a period of 8 wk resulted in a significant inhibition of tumor growth, tumor-associated angiogenic activity and neovascularization, and spontaneous lung metastases, whereas, neutralization of IP-10 for 10 wk augmented tumor growth. These findings support the notion that tumor-derived IP-10 is an important endogenous angiostatic factor in NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
O'Reilly, M. (1994) · Cell · doi:10.1016/0092-8674(94)90200-3 · Cited by 3,345
Clinical Applications of Research on Angiogenesis
Folkman, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512283332608 · Cited by 2,264
Interleukin-8 as a macrophage-derived mediator of angiogenesis
Koch, A. E., Polverini, P. J., Kunkel, S. L., Harlow, L. A., DiPietro, L. A., Elner, V. M., Elner, S. G., & Strieter, R. M. (1992) · Science · doi:10.1126/science.1281554 · Cited by 2,135 · cited 1×
“In contrast, C X C chemokines that contain the ELR motif, such as interleukin-8 (IL-8), neutrophil activating protein-2 (NAP-2), growth-related oncogene alpha (GRO-o 0, GRO-[3, G R O - y , epithelial neutrophil activating protein-78 (ENA78), and granulocyte chemotactic protein-2 (GCP-2), induce angiogenic activity at…”
Self-citationProperties Of The Novel Proinflammatory Supergene Intercrine Cytokine Family
Oppenheim, J. (1991) · Annual Review of Immunology · doi:10.1146/annurev.immunol.9.1.617 · Cited by 1,877
Control of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondin-1
Dameron, K. M., Volpert, O. V., Tainsky, M. A., & Bouck, N. (1994) · Science · doi:10.1126/science.7521539 · Cited by 1,438
The Functional Role of the ELR Motif in CXC Chemokine-mediated Angiogenesis
Strieter, R. M., Polverini, P. J., Kunkel, S. L., Arenberg, D. A., Burdick, M. D., Kasper, J., Dzuiba, J., Van Damme, J., Walz, A., Marriott, D., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.27348 · Cited by 1,222 · cited 4×
“For example, platelet factor-4 (PF-4), monokine induced by interferon-gamma (MIG), and IP-10 all lack the ELR motif and are angiostatic factors (25, 39, 40).”
InfluentialSelf-citationGood, D. J., Polverini, P. J., Rastinejad, F., Le Beau, M. M., Lemons, R. S., Frazier, W. A., & Bouck, N. P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6624 · Cited by 1,054
Self-citationLuster, A. D., Unkeless, J. C., & Ravetch, J. V. (1985) · Nature · doi:10.1038/315672a0 · Cited by 944
TUMOR DORMANCY IN VIVO BY PREVENTION OF NEOVASCULARIZATION
Gimbrone, M. A., Leapman, S. B., Cotran, R. S., & Folkman, J. (1972) · The Journal of Experimental Medicine · doi:10.1084/jem.136.2.261 · Cited by 903
Cited by
Cancer as an overhealing wound: an old hypothesis revisited
Schäfer, M., & Werner, S. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2455 · Cited by 956
The roles of IFNγ in protection against tumor development and cancer immunoediting
Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00038-7 · Cited by 899
CXC chemokines in angiogenesis
Belperio, J. A., Keane, M. P., Arenberg, D. A., Addison, C. L., Ehlert, J. E., Burdick, M. D., & Strieter, R. M. (2000) · Journal of Leukocyte Biology · doi:10.1189/jlb.68.1.1 · Cited by 804
Self-citationMig and IP-10: CXC chemokines that target lymphocytes
Farber, J. M. (1997) · Journal of Leukocyte Biology · doi:10.1002/jlb.61.3.246 · Cited by 779
Lasagni, L., Francalanci, M., Annunziato, F., Lazzeri, E., Giannini, S., Cosmi, L., Sagrinati, C., Mazzinghi, B., Orlando, C., Maggi, E., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021897 · Cited by 739
(2000) · PubMed · Cited by 706
Improving immune–vascular crosstalk for cancer immunotherapy
Huang, Y., Kim, B. Y. S., Chan, C. K., Hahn, S. M., Weissman, I. L., & Jiang, W. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.145 · Cited by 563
Neutrophil-Derived Proteins: Selling Cytokines by the Pound
Cassatella, M. A. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60791-9 · Cited by 560
The parallel lives of angiogenesis and immunosuppression: cancer and other tales
Motz, G. T., & Coukos, G. (2011) · Nature Reviews Immunology · doi:10.1038/nri3064 · Cited by 481
Phillips, R. J., Burdick, M. D., Lutz, M., Belperio, J. A., Keane, M. P., & Strieter, R. M. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200301-071oc · Cited by 455
Self-citationChemokines and Their Receptors in the Central Nervous System
Bajetto, A., Bonavia, R., Barbero, S., Florio, T., & Schettini, G. (2001) · Frontiers in Neuroendocrinology · doi:10.1006/frne.2001.0214 · Cited by 416
Numasaki, M., Watanabe, M., Suzuki, T., Takahashi, H., Nakamura, A., McAllister, F., Hishinuma, T., Goto, J., Lotze, M. T., Kolls, J. K., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.6177 · Cited by 416
CXC chemokines in angiogenesis
Strieter, R. M., Burdick, M. D., Gomperts, B. N., Belperio, J. A., & Keane, M. P. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.04.007 · Cited by 414
Self-citationCancer CXC chemokine networks and tumour angiogenesis
Strieter, R. M., Burdick, M. D., Mestas, J., Gomperts, B., Keane, M. P., & Belperio, J. A. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.006 · Cited by 410
Self-citationCutting Edge: IFN-Inducible ELR− CXC Chemokines Display Defensin-Like Antimicrobial Activity
Cole, A. M., Ganz, T., Liese, A. M., Burdick, M. D., Liu, L., & Strieter, R. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.2.623 · Cited by 382
Self-citationProtumor vs Antitumor Functions of IL-17
Murugaiyan, G., & Saha, B. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901017 · Cited by 369
Chemokines, chemokine receptors, and cancer metastasis
Kakinuma, T., & Hwang, S. T. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.1105633 · Cited by 331
SALCEDO, R., & OPPENHEIM, J. J. (2003) · Microcirculation · doi:10.1038/sj.mn.7800200 · Cited by 328
Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer
Haabeth, O. A. W., Lorvik, K. B., Hammarström, C., Donaldson, I. M., Haraldsen, G., Bogen, B., & Corthay, A. (2011) · Nature Communications · doi:10.1038/ncomms1239 · Cited by 318
Depletion of CXCR2 Inhibits Tumor Growth and Angiogenesis in a Murine Model of Lung Cancer
Keane, M. P., Belperio, J. A., Xue, Y. Y., Burdick, M. D., & Strieter, R. M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2853 · Cited by 305
Self-citationRole of CXCL1 in tumorigenesis of melanoma
Dhawan, P., & Richmond, A. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.72.1.9 · Cited by 303
Tannenbaum, C. S., Tubbs, R., Armstrong, D., Finke, J. H., Bukowski, R. M., & Hamilton, T. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.2.927 · Cited by 294
Progress in understanding the molecular pathogenesis of human lung cancer
Sekido, Y., Fong, K. M., & Minna, J. D. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00010-9 · Cited by 290
Arenberg, D. A., Keane, M. P., DiGiovine, B., Kunkel, S. L., Morris, S. B., Xue, Y. Y., Burdick, M. D., Glass, M. C., Iannettoni, M. D., & Strieter, R. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3145 · Cited by 259
Self-citationNazareth, M. R., Broderick, L., Simpson-Abelson, M. R., Kelleher, R. J., Yokota, S. J., & Bankert, R. B. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.9.5552 · Cited by 259
The multifaceted roles of chemokines in malignancy
Ben-Baruch, A. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9003-5 · Cited by 259
Fife, B. T., Kennedy, K. J., Paniagua, M. C., Lukacs, N. W., Kunkel, S. L., Luster, A. D., & Karpus, W. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.12.7617 · Cited by 256
Self-citationThe chemokine system – a major regulator of angiogenesis in health and disease
ROSENKILDE, M. M., & SCHWARTZ, T. W. (2004) · APMIS · doi:10.1111/j.1600-0463.2004.apm11207-0808.x · Cited by 255
Gasperini, S., Marchi, M., Calzetti, F., Laudanna, C., Vicentini, L., Olsen, H., Murphy, M., Liao, F., Farber, J., & Cassatella, M. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.8.4928 · Cited by 254
Chemokines as mediators of neovascularization
Keeley, E. C., Mehrad, B., & Strieter, R. M. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.162925 · Cited by 192
Self-citationIL-12 attenuates bleomycin-induced pulmonary fibrosis
Keane, M. P., Belperio, J. A., Burdick, M. D., & Strieter, R. M. (2001) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.2001.281.1.l92 · Cited by 146
Self-citationDual biological effects of the cytokines interleukin-10 and interferon-γ
Wilke, C. M., Wei, S., Wang, L., Kryczek, I., Kao, J., & Zou, W. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1104-5 · Cited by 138
Addison, C. L., Arenberg, D. A., Morris, S. B., Xue, Y.-Y., Burdick, M. D., Mulligan, M. S., Iannettoni, M. D., & Strieter, R. M. (2000) · Human Gene Therapy · doi:10.1089/10430340050015996 · Cited by 136
Self-citation
Metadata
- Authors
- Arenberg, D. A., Kunkel, S. L., Polverini, P. J., Morris, S. B., Burdick, M. D., Glass, M. C., Taub, D. T., Iannettoni, M. D., Whyte, R. I., & Strieter, R. M.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1996-09-01
- Volume
- 184
- Issue
- 3
- Pages
- 981-992
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2010003229
- Cited by
- 353
- References
- 49
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.